354 related articles for article (PubMed ID: 18495569)
1. [Premature ovarian failure after chemotherapy for breast cancer].
Mathelin C; Brettes JP; Diemunsch P
Bull Cancer; 2008 Apr; 95(4):403-12. PubMed ID: 18495569
[TBL] [Abstract][Full Text] [Related]
2. Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
Gordon AM; Hurwitz S; Shapiro CL; LeBoff MS
Menopause; 2011 Nov; 18(11):1244-8. PubMed ID: 21814159
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
[TBL] [Abstract][Full Text] [Related]
4. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
5. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).
Urruticoechea A; Arnedos M; Walsh G; Dowsett M; Smith IE
Breast Cancer Res Treat; 2008 Aug; 110(3):411-6. PubMed ID: 17851753
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
7. [Breast cancer and fertility: critical review, considerations and perspectives].
This P
Bull Cancer; 2008 Jan; 95(1):17-25. PubMed ID: 18230566
[TBL] [Abstract][Full Text] [Related]
8. Fertility preservation options for women with malignancies.
Marhhom E; Cohen I
Obstet Gynecol Surv; 2007 Jan; 62(1):58-72. PubMed ID: 17176489
[TBL] [Abstract][Full Text] [Related]
9. Impact of breast cancer treatment on fertility.
de la Haba-Rodríguez J; Calderay M
Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():59-63. PubMed ID: 20711656
[No Abstract] [Full Text] [Related]
10. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
[TBL] [Abstract][Full Text] [Related]
11. Medical approaches to preservation of fertility in female cancer patients.
Del Mastro L; Giraudi S; Levaggi A; Pronzato P
Expert Opin Pharmacother; 2011 Feb; 12(3):387-96. PubMed ID: 21254946
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility.
Franco JG; Oliveira JB; Petersen CG; Mauri AL; Baruffi R; Cavagna M
Med Hypotheses; 2012 Apr; 78(4):442-5. PubMed ID: 22284634
[TBL] [Abstract][Full Text] [Related]
13. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain.
Turner NH; Partridge A; Sanna G; Di Leo A; Biganzoli L
Ann Oncol; 2013 Sep; 24(9):2224-35. PubMed ID: 23709175
[TBL] [Abstract][Full Text] [Related]
14. A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy.
Whitehead J; Toledo MG; Stern CJ
Aust N Z J Obstet Gynaecol; 2011 Oct; 51(5):452-4. PubMed ID: 21810087
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
Furlanetto J; Marmé F; Seiler S; Thode C; Untch M; Schmatloch S; Schneeweiss A; Bassy M; Fasching PA; Strik D; Stickeler E; Schem C; Karn T; Grischke EM; Denkert C; van Mackelenbergh M; Müller V; Nekljudova V; Loibl S
Eur J Cancer; 2021 Jul; 152():193-203. PubMed ID: 34116270
[TBL] [Abstract][Full Text] [Related]
16. Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors.
McCune JS; Games DM; Espirito JL
J Oncol Pharm Pract; 2005 Jun; 11(2):37-43. PubMed ID: 16460603
[TBL] [Abstract][Full Text] [Related]
17. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.
Pérez-Fidalgo JA; Roselló S; García-Garré E; Jordá E; Martín-Martorell P; Bermejo B; Chirivella I; Guzman C; Lluch A
Breast Cancer Res Treat; 2010 Feb; 120(1):245-51. PubMed ID: 19575291
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.
Badawy A; Elnashar A; El-Ashry M; Shahat M
Fertil Steril; 2009 Mar; 91(3):694-7. PubMed ID: 18675959
[TBL] [Abstract][Full Text] [Related]
19. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P
Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118
[TBL] [Abstract][Full Text] [Related]
20. Use of goserelin in the treatment of breast cancer.
Rody A; Loibl S; von Minckwitz G; Kaufmann M
Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
